Background: A phase III trial demonstrated an overall survival advantage with the addition of
vinflunine to best supportive care (BSC) in platinum-refractory advanced urothelial cancer …

5028 Background: Second line therapy in TCCU is an unmet medical need. V is a new
microtubule inhibitor that has shown in phase II trials to be active against TCCU (Culine S …

The methotrexate, vinblastine, doxorubicin, cisplatin (M-VAC) regimen has been considered
as standard treatment of metastatic bladder carcinoma till recent years. The superiority of M …

We are more than two decades removed from the heady days of the mid-1980s when hope
that the unprecedented activity seen in advanced testes cancer by the cisplatin, vinblastine …

Purpose Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional
cell carcinoma of urothelial tract (TCCU). We conducted a randomized phase III study of VFL …

Introduction The MAJA study compared vinflunine (VFL) plus best supportive care (BSC)
maintenance therapy versus BSC alone in advanced urothelial carcinoma responsive to first …

Background There is no standard first-line chemotherapy for advanced urothelial carcinoma
(aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and …

Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in
development for the treatment of advanced transitional cell carcinoma of the urothelium …

Background Maintenance therapy improves outcomes in various tumour types, but
cumulative toxic effects limit the choice of drugs. We investigated whether maintenance …

Background The present study (VINGEM) is the first randomised trial comparing
vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with …